Risk factors for cefepime nonsusceptible Gram-negative infections in allogeneic hematopoietic cell transplant recipients

Abstract

Purpose

Allogeneic hematopoietic cell transplant recipients undergo myelosuppressive chemotherapy to allow engraftment of stem cells and are at particularly high risk for bacterial infections and adverse outcomes. Patients undergoing hematopoietic cell transplant are at increased risk for healthcare-associated infections, including infections with multidrug-resistant pathogens. Cefepime is a commonly prescribed antibiotic for empiric therapy in hematopoietic cell transplant patients, but there is minimal data describing cefepime resistance rates, risk factors for resistance, and clinical outcomes associated with cefepime-resistant infections.

Methods

Adult (≥18 years old) allogeneic hematopoietic cell transplant recipients with a culture positive for a gram-negative rod between January 2010 and January 2016 were spilt into two groups: cefepime susceptible and cefepime nonsusceptible . The primary objective of this study was to identify risk factors for cefepime nonsusceptible through multivariable logistic regression.

Results

A total of 107 patients were included (27 cefepime nonsusceptible, 80 cefepime-susceptible), yielding a 25.2% nonsusceptibility rate. Multivariable analysis yielded age >60 years old, Klebsiella spp. infection, Acinetobacter spp. infection, healthcare exposures within 90 days, acute gastrointestinal graft-vs-host-disease, and chronic graft-vs-host-disease at multiple locations as significant risk factors for cefepime nonsusceptible. The receiver operating characteristic area under the curve of the model was 0.851. Thirty-day all-cause mortality (29.6% versus 16.3%, p = 0.13) and length of hospitalization (19 versus 12.5 days, p = 0.0650) were numerically higher in the cefepime nonsusceptible group.

Conclusions

Hematopoietic cell transplant patients with acute gastrointestinal graft versus host disease, extensive chronic graft-vs-host-disease, advanced age, previous healthcare exposures, or infections with Klebsiella and Acinetobacter are at increased risk for cefepime nonsusceptible. Patients infected with cefepime nonsusceptible pathogens may have higher rates of mortality and length of hospitalization.

Keywords

Antimicrobial resistance gram-negative bacterial infections risk factors cefepime allogeneic hematopoietic cell transplantation

Get full access to this article

View all access options for this article.

References

De Bock

Middelheim

. Febrile neutropenia in allogeneic transplantation. Int J Antimicrob Agents 2000; 16: 177–180.

NCCN. Clinical Practice guidelines in oncology: prevention and treatment of cancer-related infections. v.2.2015, https://www.nccn.org/professionals/physician_gls/PDF/infections.pdf (accessed 22 June 2016).

Freifeld

Bow

Sepkowitz

et al.

Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52: e56–e93.

Oliveira

Souza

Carvalho-Dias

VMH

et al.

Epidemiology of bacteremia and factors associated with multi-drug-resistant Gram-negative bacteremia in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2007; 39: 775–781.

Guidol

Calatayud

Garcia-Vidal

et al.

Bacteremia due to extended spectrum β-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology, and outcome. J Antimicrob Chemother 2010; 65: 333–341.

Mikulska

Del Bono

Raiola

et al.

Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance. Biol Blood Marrow Transplant 2009; 15: 47–53.

Guidol

Tabau

Calatayud

et al.

Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother 2011; 66: 657–663.

Garnica

Maiolino

Nucci

. Factors associated with bacteremia due to multidrug-resistant Gram-negative bacilli in hematopoietic stem cell transplant recipients. Braz J Med Biol Res 2009; 42: 289–293.

Viscoli

Castagnola

. Treatment of febrile neutropenia: what is new? Curr Opin Infect Dis 2002; 15: 377–382.

10.

Kim

Min

Cheong

et al.

Incidence and risk factors for carbapenem- and multidrug-resistant Acinetobacter baumannii bacteremia in hematopoietic stem cell transplantation recipients. Scand J Infect Dis 2014; 46: 81–88.

11.

Balletto

Mikulska

. Bacterial infections in hematopoietic stem cell transplant recipients. Mediterr J Hematol Infect Dis 2015; 7: e2015045–e2015045.

12.

Andria

Henig

Kotler

et al.

Mortality burden related to infection with carbapenem-resistant Gram-negative bacteria among haematological cancer patients: a retrospective cohort study. J Antimicrob Chemother 2015; 70: 3146–3153.

13.

Micek

Welch

Kahn

et al.

Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother 2010; 54: 1742–1748.

14.

Bock

Cao

Ferrieri

et al.

Bacteremia in blood or marrow transplantation patients: clinical risk factors for infection and emerging antibiotic resistance. Biol Blood Marrow Transplant 2013; 19: 102–108.

15.

Paul

Robert

et al.

Research electronic data capture (REDCap) – a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42: 377–381.

16.

Przepiorka

Weisdorf

Martin

et al.

1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.

17.

Bilinski

Robak

Peric

et al.

Impact of gut colonization by antibiotic-resistant bacteria on the outcomes of allogeneic hematopoietic stem cell transplantation: a retrospective, single-center study. Biol Blood Marrow Transplant 2016; 22: 1087–1093.

18.

Docampo

Auletta

Jeng

. Emerging influence of the intestinal microbiota during allogeneic hematopoietic cell transplantation: control the gut and the body will follow. Biol Blood Marrow Transplant 2015; 21: 1360–1366.

19.

Carpenter

Kitko

Elad

et al.

National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. The 2014 ancillary therapy and supportive care working group report. Biol Blood Marrow Transplant 2015; 21: 1167–1187.

20.

Madaras-Kelly

Remington

Fan

et al.

Predicting antibiotic resistance to community-acquired pneumonia antibiotics in culture-positive patients with healthcare-associated pneumonia. J Hosp Med 2012; 7: 195–202.

21.

Horan

Logan

Agovi-Johnson

et al.

Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made?

J Clin Oncol 2011; 29: 805–813.

22.

Wang

Fan

et al.

Prevalence of resistant Gram-negative bacilli in bloodstream infection in febrile neutropenia patients undergoing hematopoietic stem cell transplantation: a single center retrospective cohort study. Medicine 2015; 94: e1931–e1931.

23.

Girmenia

Rossolini

Piciocchi

et al.

Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy. Bone Marrow Transplant 2015; 50: 282–288.

24.

Al-Anazi

Al-Jasser

. Infections caused by Acinetobacter baumannii in recipients of hematopoietic stem cell transplantation. Front Oncol 2014; 4: 186–186.

25.

Menzo

la Martire

Ceccarelli

et al.

New insight on epidemiology and management of bacterial bloodstream infection in patients with hematological malignancies. Mediterr J Hematol Infect Dis 2015; 7: e2015044–e2015044.

26.

Rosa

Goldani

dos Santos

. Risk factors for multidrug-resistant bacteremia in hospitalized cancer patients with febrile neutropenia: a cohort study. Am J Infect Control 2014; 42: 74–76.

27.

Gudiol

Garcia-Vidal

Arnan

et al.

Etiology, clinical features and outcomes of pre-engraftment and post-engraftment bloodstream infection in hematopoietic SCT recipients. Bone Marrow Transplant 2014; 49: 824–830.

28.

Marini

Hough

Gregg

et al.

Risk factors for piperacillin/tazobactam-resistant Gram-negative infection in hematology/oncology patients with febrile neutropenia. Support Care Cancer 2015; 23: 2287–2295.